Abrilada (adalimumab-afzb) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe chronic plaque psoriasis.

Acthar Gel (repository corticotropin injection) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for short-term use with other treatment during a flare of psoriatic arthritis in adults.

Amjevita (adalimumab-atto) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe chronic plaque psoriasis.

Avsola (infliximab-axxq) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with chronic severe plaque psoriasis.

Bimzelx (bimekizumab-bkzx) is a biologic medication approved by the U.S. Food and Drug Administration (FDA) for treating moderate to severe psoriasis in adults who qualify for systemic therapy (which works throughout the whole body) or phototherapy.

Overview
Calcitrene is approved by the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis in adults. It is prescribed for individuals with mild to moderate plaque psoriasis and should not be…

Cimzia (certolizumab pegol) is a biologic medication approved by the U.S. Food and Drug Administration (FDA) for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy (treatment that works throughout the whole body) or phototherapy (a treatment that uses ultraviolet light to improve psoriasis symptoms).

Cosentyx (secukinumab) is a biologic medicine approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe plaque psoriasis in people age 6 and older who need full-body treatment or light therapy.

Cyltezo (adalimumab-adbm) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe chronic plaque psoriasis and active psoriatic arthritis.

Dovonex (calcipotriene) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat plaque psoriasis.

Duobrii (halobetasol propionate and tazarotene) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with plaque psoriasis.

Enbrel (etanercept) is a biologic medication approved by the U.S. Food and Drug Administration (FDA) for treating moderate to severe psoriasis in adults and children 4 years and older.

Erelzi (etanercept-szzs) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults and children ages 4 and older with chronic moderate to severe plaque psoriasis. Note that Erelzi is not currently commercially available in the U.S.

Eticovo (etanercept-ykro) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults and children 4 years and older with moderate to severe plaque psoriasis or psoriatic arthritis.

Hadlima (adalimumab-bwwd) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe chronic plaque psoriasis and active psoriatic arthritis.

Hulio (adalimumab-fkjp) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe chronic plaque psoriasis or active psoriatic arthritis.

Humira (adalimumab) is a biologic medication approved by the U.S. Food and Drug Administration (FDA) for treating moderate to severe psoriasis in adults.

Hyrimoz (adalimumab-adaz) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe chronic plaque psoriasis and active psoriatic arthritis.

Icotyde (icotrokinra) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults and children ages 12 and older with moderate to severe plaque psoriasis.

Idacio (adalimumab-aacf) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe chronic plaque psoriasis and active psoriatic arthritis.

Ilumya (tildrakizumab-asmn) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe plaque psoriasis.

Imuldosa (ustekinumab-srlf) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults and children ages 6 and older with moderate to severe plaque psoriasis.

Inflectra (infliximab-dyyb) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with chronic severe plaque psoriasis.

Ixifi (infliximab-qbtx) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with chronic severe plaque psoriasis.

The drug maintains its official FDA…